

# Hao Li

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8537220/publications.pdf>

Version: 2024-02-01

29  
papers

248  
citations

1040056

9  
h-index

1058476

14  
g-index

29  
all docs

29  
docs citations

29  
times ranked

338  
citing authors

#	ARTICLE	IF	CITATIONS
1	H <sup>+</sup> /K <sup>+</sup> -ATPase inhibitors: a patent review. Expert Opinion on Therapeutic Patents, 2013, 23, 99-111.	5.0	32
2	Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Frontiers in Pharmacology, 2018, 9, 576.	3.5	31
3	Appraisal of Non-Cardiovascular Safety for Sodium-Glucose Co-Transporter 2 Inhibitors: A Systematic Review and Meta-Analysis of Placebo-Controlled Randomized Clinical Trials. Frontiers in Pharmacology, 2019, 10, 1066.	3.5	21
4	Grape seed proanthocyanidin extract reverses multidrug resistance in HL-60/ADR cells via inhibition of the PI3K/Akt signaling pathway. Biomedicine and Pharmacotherapy, 2020, 125, 109885.	5.6	19
5	Î± <sub>4</sub> Î² <sub>7</sub> integrin inhibitors: a patent review. Expert Opinion on Therapeutic Patents, 2018, 28, 903-917.	5.0	18
6	Left Atrial Appendage Thrombus Formation in a Patient on Dabigatran Therapy Associated With ABCB1 and CES-1 Genetic Defect. Frontiers in Pharmacology, 2018, 9, 491.	3.5	14
7	High-dose sodium-glucose cotransporter-2 inhibitors are superior in type 2 diabetes: A meta-analysis of randomized clinical trials. Diabetes, Obesity and Metabolism, 2021, 23, 2125-2136.	4.4	14
8	Phase I Clinical Study of Edaravone in Healthy Chinese Volunteers. Drugs in R and D, 2012, 12, 65-70.	2.2	11
9	A Review on Clinical Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Natalizumab: A Humanized Anti-. Current Drug Metabolism, 2018, 19, 1213-1223.	1.2	11
10	Clinical Adverse Events of High-Dose vs Low-Dose Sodium-Glucose Cotransporter 2 Inhibitors in Type 2 Diabetes: A Meta-Analysis of 51 Randomized Clinical Trials. Journal of Clinical Endocrinology and Metabolism, 2020, 105, .	3.6	10
11	Novel oxytocin receptor agonists and antagonists: a patent review (2002 - 2013). Expert Opinion on Therapeutic Patents, 2014, 24, 29-46.	5.0	8
12	Identification of microRNA biomarkers in atrial fibrillation. Medicine (United States), 2019, 98, e16538.	1.0	8
13	Grape seed proanthocyanidin extract induces apoptosis of HL-60/ADR cells via the Bax/Bcl-2 caspase-3/9 signaling pathway. Translational Cancer Research, 2021, 10, 0-0.	1.0	6
14	Intervention by clinical pharmacists can improve blood glucose fluctuation in patients with diabetes and acute myocardial infarction: A propensity score-matched analysis. Pharmacology Research and Perspectives, 2021, 9, e00725.	2.4	6
15	Beneficial Effect of Sodium-Glucose Co-transporter 2 Inhibitors on Left Ventricular Function. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 1191-1203.	3.6	6
16	Impact of Gastric H <sup>+</sup> /K <sup>+</sup> -ATPase rs2733743 on the Intragastric pH-Values of Dexlansoprazole Injection in Chinese Subjects. Frontiers in Pharmacology, 2017, 8, 670.	3.5	5
17	The Successful Rapid Adjustment of Blood Glucose in a Patient With Acute Coronary Syndrome, Renal Insufficiency, and Diabetes: A Case Report of Management Coordinated by Clinical Pharmacists and Clinicians. Frontiers in Pharmacology, 2020, 11, 756.	3.5	5
18	Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes. Medicine (United States), 2021, 100, e27044.	1.0	4

#	ARTICLE	IF	CITATIONS
19	Clinical adverse effects of natalizumab. <i>Medicine (United States)</i> , 2018, 97, e11507.	1.0	4
20	The Management of Heavy Menstrual Bleeding After Percutaneous Coronary Intervention in a Woman of Reproductive Age. <i>Frontiers in Pharmacology</i> , 2019, 9, 1573.	3.5	3
21	Pharmacokinetics of treprostinil in children with functional single-ventricle pulmonary arterial hypertension: a randomized controlled trial. <i>Annals of Translational Medicine</i> , 2021, 9, 1163-1163.	1.7	3
22	Molecular Evolution of the Vertebrate FK506 Binding Protein 25. <i>International Journal of Genomics</i> , 2014, 2014, 1-9.	1.6	2
23	Clinical adverse effects of sodium-glucose cotransporter 2 inhibitors. <i>Medicine (United States)</i> , 2018, 97, e11853.	1.0	2
24	The best pharmaceuticals for children—what can we do?. <i>Translational Pediatrics</i> , 2020, 9, 86-92.	1.2	2
25	Neutrophil to lymphocyte rate and serum prealbumin maybe predictors for abnormal high blood pressure caused by adrenocorticotrophic hormone therapy in children with epileptic spasms: two cases report. <i>Annals of Translational Medicine</i> , 2020, 8, 248-248.	1.7	1
26	Insulin-like Growth Factor 1 Promotes Cell Proliferation by Downregulation of G-Protein-Coupled Receptor 17 Expression via PI3K/Akt/FoxO1 Signaling in SK-N-SH Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1513.	4.1	1
27	Sodium-Glucose Co-Transporter 2 Inhibitors Use Improves the Satisfaction With Anti-diabetic Agent Treatment: A Questionnaire-based Propensity Score-matched Study. <i>Frontiers in Pharmacology</i> , 2021, 12, 787704.	3.5	1
28	Protocol for a systematic evaluation of pediatric pharmacy development and pediatric pharmacy experts' research area in China. <i>Medicine (United States)</i> , 2018, 97, e13597.	1.0	0
29	Sulfonylureas Use Is Not Associated With Increased Infarct Size in Patients With Type 2 Diabetes and ST-Segment Elevation Myocardial Infarction. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 658059.	2.4	0